Evrysdi – Risdiplam

Link to more information (pg, 67)


Effective March 1, 2022 – Eligibility criteria aligned with CADTH. Available through the Exceptional Drug Status Program; criteria are not public – Coverage may be available for this product through the Drug Plan for the treatment of spinal muscular atrophy. Due to the unique nature of this condition and the cost of this treatment, Exception Drug Status (EDS) requests will require additional details to facilitate assessment of the application and accompanying clinical information. In addition, patients who are approved will be required to undergo ongoing assessment to monitor for improvement over time and must meet renewal criteria for continuation of treatment.

Please contact the Drug Plan at 1-800-667-7581 for more information regarding coverage availability and the EDS application process for this product

Spinraza – Nusinersen

Link to more information



Initiation Criteria
1. Pre-symptomatic patients with 2 or 3 copies of the SMN2 gene,
2. Had the disease for <6 months, 2 copies of SMN2, and symptom onset after the first week after birth and on, or before seven months of age.
3. Patients under the age of 18 with symptom onset > 6 months of age, and never achieved the ability to walk independently. †

Stopping Criteria
1. For those pre-symptomatic at initiation: no improvement/maintenance on HINE-2, CHOP INTEND, or HFMSE, OR
2. For those symptomatic at initiation: no maintenance in HINE-2, CHOP INTENT, or HFMSE, OR
3. Permanent invasive ventilation required


“…type II and type III patients over the age of 18 are encouraged to talk to their treating physician to apply for a case-by-case coverage.”

Zolgensma – Onasemnogene abeparvovec


Exception Drug Status (EDS)